Dr. Richard Spaide Receives Multiple Recognitions and Awards

Dr. Richard Spaide was recently picked as one of the best doctors in New York by New York Magazine, one of the best physicians in the United States by “The Best Doctors in America”, and he received the Gass Award, a prestigious international accolade at the Macula Society meeting in Singapore in June 2017.

In July he won first prize in the Maculart meeting in Paris, which is a competition for medically themed artistic images and is awarded every two years. Dr. Spaide also won first prize in that competition in 2015. Dr. Spaide recently received a patent “Volume Analysis and Display of Information in Optical Coherence Tomography Angiography”.

optometrist, eye doctor, vitreous retina macula consultants of new york

Richard Spaide, MD wins the prestigious Roger Johnson Award in Macular Degeneration Research

In 2016 Dr. Spaide was awarded the Roger Johnson Memorial Award for Macular Degeneration Research from the University of Washington, which is given every two years to recognize outstanding contribution to the understanding of the pathogenesis and treatment of age-related macular degeneration by a clinician or basic science researcher working anywhere in the world. The Roger Johnson Award is one of the most prestigious awards in ophthalmology.

optometrist, eye doctor, vitreous retina macula consultants of new york

Dr. Yale Fisher Speaks at the Club Jules Gonin Meeting

Dr. Yale Fisher is speaking this week at the 30th meeting of the Club Jules Gonin in Bordeaux, France.  Dr. Fisher is speaking on ophthalmic ultrasonography, including different ways of imaging asteroid hyalosis, vitreous hemorrhage, retinal detachment, complications due to diabetic retinopathy, and visualization of the retina through dense cataracts.

optometrist, eye doctor, vitreous retina macula consultants of new york

Dr. Richard Spaide Invited to Speak at Yale Ophthalmology Spring Symposium

Dr. Richard Spaide lectured at the Yale Ophthalmology Spring Symposium/Alumni Day 2016.  He spoke on Vascular Abnormalization with Periodic Antiangiogenic Therapy in Age-Related Macular Degeneration.

Over the 45 year history of the Department of Ophthalmology and Visual Science at Yale, scientific discovery and treatment options for the range of ocular diseases have evolved into a massive body of knowledge. The faculty presenters at this symposium are contemporary experts in focused ophthalmic disciplines including cornea and external disease, glaucoma and retina, and will describe vision-saving medical and surgical therapies now considered the gold standard. This year’s symposium explored updates in pediatric ophthalmology and adult retinal disorders, in addition to comprehensive offerings in glaucoma, cornea, and visual science.

For more information about this symposium, click here.

optometrist, eye doctor, vitreous retina macula consultants of new york

Dr. Richard Spaide Receives Roger H. Johnson Macular Degeneration Award

Richard F. Spaide, MD was the recipient of the 2016 Roger H. Johnson Award, which is given every two years by the University of Washington.  The selection committee accepts nominations of clinicians and scientists throughout the world for this highly esteemed recognition.  According to the committee, “The successful candidate will be the nominee who is deemed by the selection committee to have made the most significant contribution to our understand of the pathogenesis or treatment of AMD.”

 

optometrist, eye doctor, vitreous retina macula consultants of new york

BOULEVARD Study Recruitment Begins

VRMNY is recruiting patients for the BOULEVARD study, a Phase II clinical trial for newly diagnosed diabetic macular edema (DME). Patients will be randomized to receive standard anti-VEGF Lucentis injections or a new drug that combines anti-VEGF and anti-Ang2.

Ang2 is another factor that promotes new abnormal blood vessel formation. This 7-month study will help determine if this new combination drug better preserves the vision of patients with DME. Treatments will be provided free of charge.

For more information or to see if you qualify for the study, contact our research department at research@vrmny.com or (212) 452-6965.  You may also visit the BOULEVARD Clinical Trials website.

optometrist, eye doctor, vitreous retina macula consultants of new york

MAKO Clinical Trial Begins Recruitment

Our practice has started recruiting for the MAKO clinical trial, a phase III study for newly diagnosed wet age-related macular degeneration patients. Patients will receive compensated anti-VEGF Lucentis injections with a twice-a-day squalamine eye drop.
 
MAKO is a 2 year study testing the safety and efficacy of the squalamine eye drop. This study will determine whether the drop provides an added benefit to standard anti-VEGF therapy.  Squalamine is an anti-angiogenic drug that works against abnormal neovascularization by inhibiting vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and basic fibroblast growth factor (BFGF).  This study is sponsored by Ohr Pharmaceutical Inc.
 
For more information or to see if you qualify for the study, contact our research department at research@vrmny.com or (212) 452-6965.  You may also visit the MAKO Clinical Trials website.
1 2